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This journal is ª The Royal Society ofA cyclic peptide inhibitor of C-terminal binding protein
dimerization links metabolism with mitotic ﬁdelity in
breast cancer cells†
Charles N. Birts,‡ab Sharandip K. Nijjar,‡ab Charlotte A. Mardle,ab Franciane Hoakwie,a
Patrick J. Duriez,b Jeremy P. Blaydes*bc and Ali Tavassoli*abc
Identiﬁcation of direct modulators of transcription factor protein–protein interactions is a key challenge
for ligand discovery that promises to signiﬁcantly advance current approaches to cancer therapy. Here, we
report an inhibitor of NADH-dependent dimerization of the C-terminal binding protein (CtBP)
transcriptional repressor, identiﬁed by screening genetically encoded cyclic peptide libraries of up to 64
million members. CtBP dimers form the core of transcription complexes associated with epigenetic
regulation of multiple genes that control many characteristics of cancer cells, including proliferation, survival
and migration. CtBP monomers also have distinct and critical cellular function, thus current experimental
tools that deplete all forms of a targeted protein (e.g. siRNA) do not allow the cellular consequences of this
metabolically regulated transcription factor to be deciphered. The most potent inhibitor from our screen
(cyclo-SGWTVVRMY) is demonstrated to disrupt CtBP dimerization in vitro and in cells. This compound is
used as a chemical tool to establish that the NADH-dependent dimerization of CtBPs regulates the
maintenance of mitotic ﬁdelity in cancer cells. Treatment of highly glycolytic breast cancer cell lines with the
identiﬁed inhibitor signiﬁcantly reduced their mitotic ﬁdelity, proliferation and colony forming potential,
whereas the compound does not aﬀect mitotic ﬁdelity of cells with lower glycolytic ﬂux. This work not only
links the altered metabolic state of transformed cells to a key determinant of the tumor cell phenotype, but
the uncovered compound also serves as the starting point for the development of potential therapeutic
agents that target tumors by disrupting the CtBP chromatin-modifying complex.Introduction
Molecular control of transcription factor assembly remains a
highly desirable, but signicantly challenging endeavor that
promises signicant advances in the approach to cancer
therapy.1,2 Transcription factors are considered to be some of
the most chemically intractable biological targets, but the
possibility of regulating oncogenic signaling pathways at the
earliest stages has resulted in ongoing eﬀorts in this area.3–5
Molecules capable of disrupting these key protein–protein
interactions would not only form the starting point for the
development of therapeutic agents, but also serve as chemical
tools that enable unparalleled insight into the role of tran-
scription factors in tumorigenesis and cancer cell biology.Southampton, SO17 1BJ, UK. E-mail:
sity of Southampton, Southampton, SO16
thampton, UK
tion (ESI) available. See DOI:
is work.
Chemistry 2013Constitutively upregulated aerobic glycolysis, a phenotype
knownas theWarburg eﬀect, is a key feature of cancer cells;6,7 the
resulting changes in intracellular metabolite concentrations
further aﬀect metabolic pathways8,9 and lead to altered regula-
tion of critical signalingmolecules and transcription factors.7,9,10
Acquired mutations in genes that control the stringency of cell
cycle checkpoints also provide an advantage to cancer cells by
increasing both the rate of cell division and the degree of
genomic instability.6 Evidence from a number of independent
studies has recently uncovered bidirectional interplay between
the regulators and sensors of glycolytic metabolism and
processes that control genome stability and transit through
mitosis,9,11–15 potentially linking two key determinants of cancer
cells viametabolite sensing transcriptional regulators.
The two vertebrate C-terminal binding proteins (CtBP1 and
CtBP2) are highly homologous metabolic sensors with unique
and overlapping roles during development.16 The central region
of both CtBPs contains a NADH-dependent homo- and hetero-
dimerization domain17,18 that promotes dimerization in
response to elevated NADH levels. CtBP dimers nucleate the
assembly of chromatin modifying complexes (including
various histone deacetylases and histone demethylases)19 thatChem. Sci.
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View Article Onlineare recruited to chromatin through their association with
over 30 diﬀerent DNA-binding transcription factors (via CtBP-
binding motifs PXDLS and RRT).20,21 Interestingly, a number of
distinct activities have also been specically attributed to the
NADH-unbound forms of CtBPs, including interaction with
specic transcriptional regulators,22,23 maintenance of Golgi
membrane architecture,24 and transcriptional activation of
Wingless pathway targets.25 This latter study in particular
clearly demonstrates that deciphering the role of CtBPs in the
control of cellular responses to altered glycolytic metabolism is
highly dependent on the availability of tools that manipulate
the dimerization status of CtBPs in cells.
NADH-dependent CtBP dimerization is thought to cause
transcriptional repression of a broad network of genes that
respond to the tumor cell phenotype.26,27 As NADH is a key
indicator of glycolytic cells,8,28 the CtBP family of proteins may
be considered key regulators of the phenotype of highly glyco-
lytic tumor cells.17,26,27 The role of CtBPs as metabolic sensors
that control cell survival and migration in response to increased
hypoxic and aerobic glycolysis has been demonstrated,29,30 with
down-regulation of CtBP-targeted genes distinguishing the
aggressive subtype of breast cancer.31 Furthermore, elevated
nuclear CtBP levels has recently been shown to correlate to poor
survival in breast cancer patients.31
Use of siRNA or dominant negative CtBP fragments have
revealed the requirement for interaction of CtBPs with PXDLS
motif-containing factors in the nucleus in interphase for
normal progression through the subsequent mitosis;32,33
knockdown of CtBPs results in the activation of an extended
spindle assembly checkpoint prior to the completion of an
aberrant mitosis, and the generation of daughter cells with an
abnormal chromosome content.32,33 Aberrant chromosome
segregation, caused by failures in the spindle assembly check-
point, leads to defects in cytokinesis and the generation of
aneuploid or polyploid daughter cells, a feature of many cancer
cells that facilitates the acquisition of further genetic mutation.
Experimental reduction of the stringency of this checkpoint
either promotes tumor formation, or where a mitotic defect is
so severe as to be incompatible with cell survival, inhibits tumor
growth;34 CtBP-depleted cells undergo apoptosis, unless pro-
tected by a p53 checkpoint in G1.32
The above studies have not established whether it is the
monomeric or NADH-bound dimeric forms of CtBPs that are
critical for this process, limiting our fundamental under-
standing of how the Warburg eﬀect drives tumorigenesis. It is
currently not clear whether the conversion of CtBP monomers
to dimers (that occurs in highly glycolytic tumour cells)
increases mitotic delity and hence promotes proliferation, or
has the opposing eﬀect on mitosis, thus promoting tumori-
genesis though increasing genomic instability. Conventional
methods such as gene knockout or siRNA knockdown are not
able to address this question as they equally deplete monomeric
and dimeric CtBPs, and whilst NADH-binding mutants of CtBPs
can be used, it is diﬃcult to ensure that they will be expressed at
the correct stoichiometry with their interacting partners to
avoid possible dominant negative eﬀects. A molecular modu-
lator of CtBP dimerization would therefore serve as a valuableChem. Sci.chemical tool that advances our understanding of how these
key processes in cancer biology are linked. In addition to this,
pharmacological targeting of CtBPs has long been proposed as a
promising approach to disrupting the links between the meta-
bolic and epigenetic networks that are responsible for the
malignant reprogramming of cells.26 The only currently known
CtBP inhibitor is 2-keto-4-methylthiobutyrate (MTOB),35,36 an
intermediate in the methionine salvage pathway that has been
shown to reverse the repression of the pro-apoptotic gene BIK
in colon cancer cells,36 and to reverse the repression of multiple
CtBP-targeted genes in breast cancer cells.31 MTOB acts as a
substrate for the pyruvate binding pocket on the catalytic
dehydrogenase domain of CtBPs, with high concentrations of
MTOB inhibiting the recruitment of CtBPs to target
promoters.37 As a consequence of its mode of action, MTOB
has to be used at high concentrations to elicit a cellular
response (4 mM and 10 mM in the studies cited above).31,36
We therefore set out to identify a molecular modulator of
CtBP dimerization using a genetically encoded high-throughput
screening platform that rapidly assesses SICLOPPS (split-intein
circular ligation of peptides and proteins) cyclic peptide
libraries of up to a hundred million members38,39 for inhibitors
of a given protein–protein interaction.40,41 The identied
compounds would not only enable the role of the NADH-
dependent dimerization of CtBP1 and CtBP2 in maintaining
mitotic delity in rapidly dividing breast cancer cells to be
determined, they would serve to further validate the role of
CtBPs in driving tumorigenesis, and also form the starting point
for the development of potential therapeutic agents that target
the epigenetic changes that drive cancer cell phenotypes.Results
Knockdown of CtBPs increases aberrant mitosis in highly
glycolytic cells
We have previously demonstrated that the combined knock-
down of both CtBP1 andCtBP2 by siRNA causes aberrantmitosis
inMCF-7 cells.32We conducted further experiments using siRNA
targeting CtBP1 or CtBP2 individually and demonstrated that
depletion of both proteins is required to cause this phenotype in
MCF-7 cells (Fig. 1a, in which we present the accumulation of
micronuclei; a cumulative measure of cells that have undergone
mitosis with aberrant chromosome segregation). To determine
the eﬀect of cellular glycolytic state on the consequences of CtBP
loss, we compared micronuclei formation in CtBP-depleted
HeLa cells cultured in either 25 mM glucose or 10 mM fructose.
This change in sugar source alters the metabolism of HeLa from
highly glycolytic (with glucose) to essentially non-glycolytic with
a high dependency on glutaminolysis (with fructose).42 We
observed comparable levels of micronuclei in CtBP-depleted
HeLa cells cultured with 25 mM glucose, as that observed for
the highly glycolytic MCF-7 breast cancer cells (Fig. 1b). In
contrast, CtBP-depletion in HeLa cells grown in 10 mM fructose
did not aﬀect micronuclei formation. These data demonstrate
that a switch to glycolytic metabolism renders these cancer
cells dependent upon CtBPs for their ability to accurately
execute cell division. Given the pre-established literature on theThis journal is ª The Royal Society of Chemistry 2013
Fig. 1 CtBP knockdown increases micronuclei formation in glycolytic cells. (a) The eﬀect of individual and combined knockdown of CtBP1 and CtBP2 on micronuclei
formation in MCF-7 cells. CtBP siRNA targeting a common region in both CtBP1 and CtBP2 has been described previously, as have siRNAs targeting individual CtBP1 and
CtBP2 mRNAs.32 Eﬀectiveness of siRNA knockdown is shown in Fig. S1.† (b) The eﬀect of upregulated glycolysis on the requirement for CtBPs for the maintenance of
mitotic ﬁdelity. Cells cultured in medium containing either glucose or fructose were transfected with the indicated siRNA.
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View Article Onlinemolecular control of CtBP function by glycolysis-derived
NADH, we hypothesize that the NADH-dependent dimerization
of CtBPs is critical in this process. To enable better testing of
this hypothesis, we therefore sought to identify a molecular
modulator of the dimerization of both CtBP1 and CtBP2
in cells.Identication of cyclic peptide inhibitors of CtBP
dimerization
We began by constructing a bacterial reverse two-hybrid system
(RTHS), to link the survival of a host strain of E. coli on selective
media to the disruption of CtBP1 homodimers fused to the
bacteriophage 434 repressor. Homodimerization of the CtBP1
fusion protein reconstitutes the 434 repressor, which binds to
operator sites incorporated onto the E. coli chromosome, pre-
venting the expression of three downstream reporter genes
(Fig. 2a), resulting in cell death on selective media. The
repressor complex does not form if the targeted proteins do
not interact or in the presence of an inhibitor of the targetedFig. 2 CtBP reverse two-hybrid system. (a) CtBP expression as fusions with the 4
proteins associate to form a functional repressor that prevents expression of the repo
gene, LacZ is used to quantify the protein–protein interaction by o-nitrophenyl-b-D
RTHS. (c) Drop-spotting serial dilutions (2.5 mL of10n cells per mL) of the CtBP1, CtB
and without IPTG. Data shows formation of a functional repressor in all cases excep
This journal is ª The Royal Society of Chemistry 2013protein–protein interaction, allowing expression of the reporter
genes and survival of the host cell on selective media. CtBP1
homodimerization and formation of a functional repressor was
conrmed by IPTG-dependent reduction of b-galactosidase
activity (Fig. 2b) and inhibition of cell growth by drop spotting
onto selective media (Fig. 2c). A CtBP2 RTHS was also con-
structed and shown to be functional using the same approach
(Fig. 2b and c). A control RTHS built using a NADH-binding
incompetent mutant of CtBP2 (CtBP2G189A),22 did not show the
formation of a functional repressor (Fig. 2b and c), demon-
strating that the observed inhibition of cell growth in the CtBP1
and CtBP2 RTHS is due to NADH-dependent homodimerization
of the target proteins.
Three cyclic peptides libraries synthesized in vivo using split
intein circular ligation of peptides and proteins (SICLOPPS)38,39
were separately screened for CtBP1 inhibitors using the CtBP1
RTHS: a 1.6  105 member SGW+4 (SGWXXXX, X ¼ any amino
acid) cyclic heptamer library; a 3.2  106 member SGW+5
(SGWXXXXX) cyclic octamer library; and a 6.4  107 member
SGW+6 (SGWXXXXXX) cyclic nonamer library. The libraries34 bacteriophage DNA binding protein is induced by IPTG. The CtBP-434 fusion
rter genes HIS3 and KanR, inhibiting growth on selective media. The third reporter
-galactoside (ONPG) assays. (b) ONPG assay of the CtBP1, CtBP2 and CtBP2G189A
P2, CtBP2G189A, and ATIC (positive control)41 RTHS onto selective media plates with
t the dimerization-incompetent CtBP2G189A RTHS.
Chem. Sci.
Table 1 Top 3 CtBP1/CtBP2 inhibitors identiﬁed by SICLOPPS
Rank Name Target Peptide sequence
1 CP61 CtBP1/CtBP2 SGW TVVRMY
2 CP68 CtBP1/CtBP2 SGW PLSTWY
3 CP65 CtBP1/CtBP2 SGW RLIRLY
Chemical Science Edge Article
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View Article Onlinecontained an invariable motif of serine (required nucleophile
for intein processing), glycine (prevents racemization during
chemical synthesis) and tryptophan (functions as a chromo-
phore for HPLC purication). Transformation of the CtBP1
RTHS with SICLOPPS plasmids results in the expression of split-
inteins (under control of an arabinose promoter) that process to
give the corresponding cyclic peptides. Only plasmids encoding
cyclic peptides able to disrupt the homodimerization of CtBP1
enable survival of the host strain on selective media. 104
surviving colonies were picked from selection plates, the
SICLOPPS plasmids were isolated from these colonies and
transformed back into the CtBP1 RTHS for rescreening; 44 of
these plasmids caused the expected phenotypes in the CtBP1
RTHS. Non-specic inhibitors that functioned by targeting
components of the RTHS other than the CtBP dimer were
identied and excluded using an otherwise identical RTHS
monitoring the homodimerization of ATIC (aminoimidazole
carboxamide ribonucleotide transformylase/inosine mono-
phosphate cyclohydrolase, a homodimeric enzyme that cata-
lyzes the last two steps of the de novo purine biosynthesis
pathway),41 yielding 23 cyclic peptide CtBP1 inhibitors. We
probed the isolated CtBP1 inhibitors for the ability to also
disrupt CtBP2 homodimerization using the CtBP2 RTHS. 19 of
these peptides disrupted both CtBP1 and CtBP2 homodimeri-
zation; the SICLOPPS plasmids encoding the three most potent
compounds (ranked by drop spotting) were sequenced to reveal
their identity (Table 1). Arabinose-promoted production of the
most potent cyclic peptide, cyclo-SGWTVVRMY (Fig. 3a),
enabled cell survival on minimal media in the CtBP1 or CtBP2
RTHS (Fig. 3b).Fig. 3 Cyclic peptide CtBP dimerization inhibitors. (a) Structure of CP61. (b) Drop s
selective media with 50 mM IPTG, with and without arabinose (induces expression
dimerization of CtBPs.
Chem. Sci.All three CtBP1/CtBP2 inhibitors were identied from the
SGW+6 library, with two (CP61 and CP65) containing a
seemingly related pentapeptide region of two aliphatic amino
acids (V/L then V/I), followed by an RXY motif, suggesting the
same structural feature being targeted by both inhibitors. The
most potent inhibitor, CP61 (Fig. 3), was synthesized by solid-
phase peptide synthesis and carried forward for validation
in vitro.CP61 inhibits the dimerization of CtBPs in vitro
The ability of CP61 to disrupt the homodimerization of both
CtBPs was probed in a series of in vitro experiments using
recombinant proteins. We initially used a GST pull down assay
to demonstrate that the NADH-dependent association between
GST–CtBP1 and His–CtBP1 is disrupted by CP61 (Fig. 4a). To
quantify the potency of CP61 an ELISA (enzyme-linked immu-
nosorbent assay) was developed for the NADH-dependent
homodimerization of CtBP2. This assays showed that CP61
inhibits the homodimerization of CtBP2 with an IC50 of 19 
4 mM (Fig. 4b). This value is comparable to that of previously
reported cyclic peptide inhibitors of other protein–protein
interactions identied with SICLOPPS.40,41,43 We next used size
exclusion chromatography to directly probe the eﬀect of CP61
on the CtBP dimer to monomer equilibrium. In the absence of
NADH, a peak corresponding to monomeric CtBP1 was
observed that upon the addition of NADH, shied to a peak
corresponding to dimeric CtBP1 in a dose-dependent manner
(Fig. 4c). Addition of CP61 to a solution of dimeric CtBP1 (CtBP1
incubated with 10 mM NADH) caused a dose-dependent shi
back to the monomeric species (Fig. 4d), further demonstrating
disruption of CtBP1 dimerization by CP61.
We next sought to probe the mechanism of action of CP61
using a previously reported assay that quanties the binding of
NADH to CtBP1, by monitoring the Fo¨rster Resonance Energy
Transfer (FRET) between a tryptophan in the CtBP NADH
binding pocket and NADH (tryptophan excited at 285 nm,
NADH emission monitored at 425 nm).17 The observedpotting of the CtBP1 or CtBP2 RTHS containing the plasmid encoding CP61 onto
of SICLOPPS). Restoration of growth with arabinose suggests that CP61 disrupts
This journal is ª The Royal Society of Chemistry 2013
Fig. 4 Analysis of the inhibition of CtBP dimerization by CP61 in vitro. (a) Left hand panel shows GST–CtBP1 capturing increasing amounts of His–CtBP1 with increasing
concentrations of NADH, as quantiﬁed in the middle panel. Right hand panel shows GST–CtBP1 capturing His–CtBP1 in the absence or presence of NADH and CP61,
showing disruption of CtBP1 dimerization by CP61. (b) GST–CtBP2 and His–CtBP2 were incubated with CP61 prior to the addition of NADH and quantiﬁcation of CtBP2
dimer formation by ELISA. Data points are mean  SD of two independent experiments, each with triplicated wells. (c) Size exclusion chromatography of His–CtBP1
shows transition of monomer to dimer upon addition of increasing concentrations of NADH. (d) Size exclusion chromatography of His–CtBP1 with 10 mMNADH shows
dose-dependent disruption of dimer formation by CP61. (e) A FRET-based CtBP1/NADH-binding assay shows a dose dependent reduction in FRET signal (at 425 nm)
with increasing CP61, suggesting allosteric inhibition by CP61. Data ﬁtted by nonlinear regression. (f) NADH–CtBP1 interaction by FRET shows the eﬀect of increasing
CP61 concentration with NADH ﬁxed at 1 mM. X-axis is plotted on a log scale to demonstrate saturation of binding at higher CP61 concentrations.
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View Article OnlineNADH-dependent increase in the FRET signal was reduced
upon addition of CP61, in a dose-dependent manner, demon-
strating that CP61 inhibits the CtBP1–NADH interaction.
Furthermore, as the maximum FRET signal at saturating NADH
concentrations was reduced in a CP61-dependent manner
(Fig. 4e), an allosteric mechanism for inhibition of NADH-
binding by CP61 may be inferred; CP61 does not bind to the
NADH-binding pocket on CtBP1, but indirectly inhibits FRET by
disrupting the protein–protein interaction.
The mode of action and binding aﬃnity of CP61 for CtBP1
were further probed by monitoring the loss of FRET caused by
titrating increasing concentrations of CP61 into a mixture of
dimeric CtBP1 (with NADH xed at 1 mM). This resulted in a
biphasic binding curve, indicating that CP61 binds dimeric
CtBP1 with an aﬃnity of 3 mM and 11 mM (Fig. 4f). The diﬀer-
ential binding aﬃnity observed suggests that CP61 binds to two
forms of CtBP1 molecules; this may be interpreted as indicatingThis journal is ª The Royal Society of Chemistry 2013diﬀerential access of CP61 to its binding sites dependent upon
the oligomeric state of the CtBP protein (monomer vs. dimer)
and/or its prior binding to NADH (which changes the confor-
mation of CtBPs).
The NADH-binding domain of CtBPs resembles a Rossmann
fold that is characteristic of a large number of NADH-dependent
dehydrogenases.44 Given that the FRET experiments demon-
strated CP61 is able to disrupt NADH-binding to this domain,
we considered it important to establish whether CP61 demon-
strates selectivity for CtBPs compared to other proteins that
contain an NAD+/NADH dependent dehydrogenase domain.
Such dehydrogenases may be the most likely source of any
potential oﬀ-target eﬀects of CP61 in cancer cells. CP61 (at
concentrations of up to 100 mM) had no eﬀect on the activity of
lactate dehydrogenase (Fig. S2†), demonstrating that its ability
to disrupt NADH-Rossmann fold binding is selective for the
CtBP dehydrogenase domain.Chem. Sci.
Chemical Science Edge Article
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View Article OnlineCP61 disrupts CtBP dimerization in cells
The eﬀect of CP61 on intracellular CtBP dimerization was
examined using an assay based on the ability of CtBP hetero-
dimers to direct the subcellular localization of CtBP1.45 CtBP2
has a nuclear localization sequence and is therefore primarily
localized in the nucleus when overexpressed in COS-7 cells
(Fig. 5a). In contrast, CtBP1 lacks this sequence and has a
predominantly cytoplasmic distribution in this assay (Fig. 5b).
Co-expression of the two CtBPs results in accumulation of
CtBP1 to the nucleus (Fig. 5c) in a dimerization-dependent
manner;45 disruption of this protein–protein interaction by
CP61 would be expected to reduce the nuclear accumulation of
CtBP1. To aid internalization of CP61 into cells, the cell-pene-
trating sequence of the HIV TAT internalization domain
(GRKKRRQRRRPPQ) was attached to CP61 via a disulde bond,
formed by modifying the preset region of the cyclic peptide
from SGW to CGW and by adding a cysteine to the N-terminus
of TAT. In control cells treated with 100 mM TAT, CFP–CtBP1
showed the expected co-localization with YFP-CtBP2 in the
nucleus (Fig. 5d and f), with 13.5% demonstrating quantiableFig. 5 CP61 disrupts CtBP dimerization in cells. (a) Subcellular localization of YFP
localization of CFP–CtBP1 in COS-7 transfected with a plasmid encoding CFP–CtBP1.
with plasmids encoding both proteins. (d and e) Cells transfected as in (c) were pre
peptides on inhibiting the CFP–CtBP2-dependent relocalisation of YFP–CtBP1 out of
applied to CFP image (middle panel) to demonstrate ﬂuorescence intensity. (f and g)
respectively. Overlapping peaks demonstrate co-localization in the nucleus. Arrows i
localization with YFP–CtBP2 in the nucleus. (h) Results of line analysis of cells treate
CtBP1. Number of cells analyzed in brackets. * ¼ statistical diﬀerence from TAT-trea
Chem. Sci.cytoplasmic CFP–CtBP1 (Fig. 5h). There was amarked reduction
in the nuclear co-localization of CtBPs in cells treated with
100 mM CP61–TAT (Fig. 5e and g); whilst YFP–CtBP2 remained
almost exclusively nuclear, CFP–CtBP1 was clearly detectable in
the cytoplasmic compartment of 71.1% of cells analyzed
(Fig. 5h). Importantly, CP61–TAT does not aﬀect the cellular
quantity of CtBP1 or CtBP2 (Fig. S1†); this data demonstrates
that CP61–TAT disrupts CtBP dimerization in cells.
CtBP dimerization maintains mitotic delity in MCF-7 breast
cancer cells
Having demonstrated that CP61 disrupts CtBP dimers in vitro
and in cells, we sought to use our inhibitor as a chemical tool to
decipher the role of NADH-dependent CtBP dimerization in the
maintenance of mitotic delity in rapidly dividing breast cancer
cells. The accumulation of micronuclei was initially used to
measure the eﬀect of CP61–TAT on the mitotic delity of MCF-7
cells. As illustrated in (Fig. 6a) micronuclei and evidence of
gross mitotic abnormalities were detectable in cells exposed to
50 mM CP61–TAT. A dose–response assay was therefore–CtBP2 in COS-7 transfected with a plasmid encoding YFP–CtBP2. (b) Subcellular
(c) Subcellular localization of YFP–CtBP2 and CFP–CtBP1 in COS-7 cells transfected
-treated with 100 mM TAT (d) or 100 mM CP61–TAT (e) to assess the eﬀect of the
the cytoplasm and into nucleus. Right hand images shows rainbow lookup table
Line analysis (along red line) of the YFP and rainbow lookup images in (d) and (e)
n (e) and (g) show cytoplasmic CFP–CtBP1 due to CP61–TAT-induced loss of its co-
d with 100 mM TAT or 100 mM CP61–TAT, scored for presence of cytoplasmic CFP–
ted cells (P ¼ 0.0011 Fishers exact contingency table).
This journal is ª The Royal Society of Chemistry 2013
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View Article Onlineperformed, comparing CP61–TAT to TAT alone (Fig. 6b).
Approximately 7% of MCF-7 cells treated with up to 100 mM of
TAT contained micronuclei (Fig. 6b). The addition of 10 mM,
50 mM or 100 mM of CP61–TAT resulted in a dose dependent
increase in the percentage of cells that contained micronuclei
(9.4%, 15.1%, and 17.3% respectively) (Fig. 6b). The eﬀects of
CP61–TAT at both 50 mM and 100 mM were signicant (P < 0.01)
compared to TAT alone, and are comparable to levels previously
reported for cells treated with CtBP siRNA (Fig. 1a and ref. 32).
We next used time-lapse video-microscopy to study the
eﬀects of CP61–TAT on the delity of MCF-7 mitosis in real-
time. Aberrant mitosis phenotypes (including being rounded
for extended period of time and/or failed cytokinesis or death)
were scored from video images taken over a 65 hour period
following treatment with CP61–TAT. The extended activation ofFig. 6 Eﬀect of cell CP61–TATonmitotic ﬁdelity in breast cancer model cells. (a) Rep
binucleate cells. Cells in left-hand panel are stained with DAPI (nuclei); cells in right
MCF-7 cells were incubated with the indicated peptide and ﬁxed for micronuclei
representative images of cells scored in this assay. (c) MCF-7 cells were treated as indi
cell was scored for morphological features of abnormality. Bars indicate the mean
substantially reduce the proportion of cells that undergo mitosis (Fig. S4a†). Represe
time in mitosis was scored for cells in (c), red bars show mean time in mitosis. (e) T
number during the ﬁrst 48 hours of analysis. (f) MDA-MB-231 cells were treated as i
each cell was scored for morphological features of abnormality. The peptides did no
data is presented as in (c). (g) The eﬀect of CP61–TAT compared to TAT alone on th
This journal is ª The Royal Society of Chemistry 2013the spindle assembly checkpoint in response to aberrant
mitosis was also quantied by determining the length of time
each individual cell takes to traverse through mitosis. Cells
treated with 50 mM CP61–TAT showed a signicant increase in
the percentage of cells in which mitosis was aberrant from 3.5%
(in control treated cells) to 27.5% (P ¼ 0.0002) (Fig. 6c and ESI
videos 1 and 2†). The mean time in mitosis of CP61–TAT-treated
cells also increased from 1.2 h to 3.5 h (Fig. 6d). These eﬀects
correlated with a 2-fold reduction of proliferation in MCF-7
cells treated with CP61–TAT (Fig. 6e). In cells treated with 50 mM
TAT there was a 111% increase in cell numbers in 48 hours,
whereas only a 71% increase was observed in cells treated with
50 mM CP61–TAT. In these experiments the numbers of cells
undergoing mitosis was not substantially aﬀected by CP61–TAT
(Fig. S4†), indicating that the above observations are not due toresentative images of CP61–TAT-treatedMCF-7 cells showing (i) micronuclei and (ii)
-hand panel are stained with DAPI (nuclei, blue) and FITC (actin ﬁbers, green). (b)
analysis after 48 h. >400 cells were scored for each data-point; see Fig. S3† for
cated and imaged by time-lapse videomicroscopy for 65 h. The ﬁrst mitosis of each
values. Number of mitoses scored is shown in parenthesis. The peptides did not
ntative time-lapse sequences are shown in ESI videos 1 and 2.† (d) The length of
he eﬀect of CP61–TAT compared to TAT alone on the increase in total MCF-7 cell
ndicated and imaged by time-lapse video microscopy for 65 h. The ﬁrst mitosis of
t substantially reduce the proportion of cells that undergo mitosis (Fig. S4b†). The
e increase in total MDA-MB-231 cell number during the ﬁrst 48 hours of analysis.
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View Article Onlinenon-selective toxicity of CP61–TAT. To demonstrate the cell-
line independence of these observations, the above time-lapse
microscopy experiments were repeated in the oestrogen
receptor negative, and highly metastatic MDA-MB-231 cell line,
with comparable results (Fig. 6f and g).
To establish that the above eﬀects of CP61 were independent
of potential inuence from delivery by TAT, CP61 (untagged)
was microinjected into synchronized MCF-7 cells in early S
phase, and the delity of the subsequent mitosis was deter-
mined by time-lapse video-microscopy analysis as before.
Compared to control-injected cells, CP61 caused a signicant
(P < 0.001) increase in the percentage of mitoses that were
aberrant from 1.6% to 46.1% (Fig. 7a–c, and ESI videos 3–5†).
CP61 also increased the mean length of time each cell spent in
mitosis from 1.4 h in control-injected cells to 3 h (Fig. 7a, b and
d), consistent with that observed for CP61–TAT.
To conrm that the observed loss of mitotic delity is caused
by the disruption of CtBPs by CP61, we employed an alternative
approach to study the disruption of functional CtBP dimers in
cells. We have previously used dominant negative fragments
of CtBP2 to assess the protein interactions involved in the
CtBP-dependent regulation of mitotic delity.33 Here, we used aFig. 7 Eﬀect of microinjected CtBP dimerization inhibitors on mitotic ﬁdelity of cel
Montages showing examples of mitoses in MCF-7 cells injected with FITC-dextran
(green); the cell in the center of the image is undergoing an extended mitosis, as ev
control treated cells (panel (a), 1.0 h frame only). Also see ESI videos 3–5.† (c) The per
for MCF-7 cells injected with FITC-dextran (FITC), CP61 + FITC-dextran (CP61) or non-
Each mitotic cell assessed in (c) was scored for the length of time in mitosis. Red line
was phenotypically abnormal was scored for MCF-7 cells injected with GST–CtBPD
proteins into MCF-7 cells. Numbers in brackets indicate number of cells assessed. (f)
mean time in mitosis. The above CtBP dimerization inhibitors did not substantially r
Chem. Sci.construct encoding the central dimerization domain (110–359)
of CtBP2 (GST–CtBPDD) that is designed to bind endogenous
CtBP monomers, and thus prevent the formation of functional
CtBP dimers. A plasmid encoding a dimerization-incompetent
(R147L, R169L)46 variant of this (GST–CtBPDDM) was used as a
control. An aberrant mitosis phenotype was observed in 45% of
cells injected with GST–CtBPDD, whereas #14% of cell injected
with GST alone, or CtBPDDM showed this phenotype (Fig. 7e).
GST–CtBPDD also increased the time in mitosis, in line with that
observed in CP61-treated cells, whereas the dimerization-
incompetent mutant had no eﬀect (Fig. 7f).CP61 does not aﬀect mitotic delity of less glycolytic MDA-
MB-453 breast cancer cells
As we demonstrated in Fig. 1a usingmanipulation of the culture
medium of HeLa cells, dependency on CtBPs for the execution
of accurate mitosis is a feature of cells with high glycolytic ux,
whereas in cells with low glycolytic ux mitotic delity is
insensitive to CtBP loss. As this not only demonstrates a hith-
erto unrecognised link between glycolysis and the molecular
control of mitosis, but also has important implications as to thel cycle synchronized MCF-7 cells, quantiﬁed using time-lapse video microscopy. (a)
(green). (b) Montage of mitosis in MCF-7 cells injected with CP61 + FITC-dextran
ident from the prolonged period of rounding (0.5 h to 2.0 h frames) compared to
centage of cells in which the ﬁrst mitosis was phenotypically abnormal was scored
injected cells (none). Numbers in brackets indicate number of mitoses assessed. (d)
shows average time in mitosis. (e) The percentage of cells in which the ﬁrst mitosis
D (DD) or the dimerization incompetent GST–CtBPDD(R147L,R169L) analogue (DDM)
Each mitotic cell in (e) was scored for the length of time in mitosis. Red bars show
educe the proportion of cells that undergo mitosis (Fig. S5†).
This journal is ª The Royal Society of Chemistry 2013
Fig. 8 Comparing the eﬀect of CP61 on the mitotic ﬁdelity of MCF-7 and MDA-
MB-453 cells. (a) The percentage of cells in which the ﬁrst mitosis was pheno-
typically abnormal was scored for MCF-7 and MDA-MB-453 cells injected with
FITC-dextran (FITC), CP61 + FITC-dextran (CP61) or non-injected cells (none).
Numbers in brackets indicate number of mitoses assessed. (b) Each mitotic cell
assessed in (a) was scored for the length of time in mitosis. Red bars show mean
time in mitosis.
Fig. 9 Inhibition of CtBP dimerisation inhibits clonogenic survival of MCF-7
cancer cells. Cells were treated for 48 hwith 50 mMCP61–TAT, 50 mMTATor DMSO
carrier control, and re-plated for 10 day colony forming assays. Bars showmean
SEM for triplicate wells from a representative of three independent experiments.
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View Article Onlineultimate use of CtBP dimerisation inhibitors for the therapy of
highly glycolytic tumours, we sought to determine whether the
eﬀects of CP61–TAT on mitosis are similarly dependent on
glycolysis. In order to use an alternative model system to HeLa
cells cultured in fructose, we compared breast cancer cell lines
with well characterised diﬀerences in their rates of glycolysis.47
In analogous experiments to those in Fig. 7, the eﬀect of CP61
on the mitotic delity of the highly glycolytic MCF-7 cell line,
was compared with its eﬀect on MDA-MB-453, which demon-
strate constitutively low rates of glycolysis, even when cultured
in high glucose, and instead rely heavily on glutamine oxida-
tion.47 Cells were assessed by microinjection and time-lapse
video-microscopy. In MCF-7, compared to control-injected cells,
CP61 again caused a signicant (P < 0.0001) increase in the
percentage of mitoses that were aberrant from 10.2% to 50.8%
(Fig. 8a). Themean length of time each cell spent inmitosis also
increased from 1.9 h in control-injected cells to 4 h aer CP61
injection (Fig. 8b), consistent with earlier observations (Fig. 7c
and d). In contrast, when injected into MDA-MB-453 cells CP61
did not signicantly aﬀect the percentage of mitoses that were
aberrant (P > 0.05) compared to control-injected cells (Fig. 8a).
CP61 also did not aﬀect the length of time MDA-MB-453 cells
spent in mitosis (Fig. 8b). These ndings support our hypoth-
esis that the disruption of CtBP dimerization by CP61 will only
aﬀect mitotic delity in highly glycolytic cells. Additionally, this
data provides further evidence that the cellular eﬀects of CP61
are due to its on-target eﬀects on CtBPs, as the deleterious
eﬀects of both CtBP knockdown and CP61 onmitotic delity are
both selectively associated with a high rate of glycolytic ux.Colony forming potential of breast cancer-derived cells is
suppressed by CP61
Results from our time-lapse experiments (Fig. 6e and g)
demonstrated the ability of CP61–TAT to suppress the prolif-
eration of cancer cell lines in short term assays. To determine
whether this represented a transient arrest, from which the cells
could later recover, or a long-term loss of proliferative potentialThis journal is ª The Royal Society of Chemistry 2013through the induction of cell death or senescence, colony
forming assays were performed. MCF-7 cells were treated with
50 mMCP61–TAT for 48 hours, plated, and incubated for 10 days
to assess their colony forming potential. Compared to cells
treated with either carrier alone or 50 mM TAT, exposure to
50 mM CP61–TAT for 48 h resulted in a signicant (P < 0.05) 3-
fold reduction in the number of colonies formed (Fig. 9),
demonstrating the anti-proliferative potential of CP61.
Together, our ndings demonstrate that the dimeric form of
CtBPs is required for maintenance of normal mitotic delity in
rapidly dividing breast cancer cells, suggesting that cellular
glycolytic state is linked to mitotic cell cycle checkpoint control
through the regulation and detection of extra-mitochondrial
free NADH concentrations by CtBPs. Loss of this important
regulatory function of CtBPs results in the long term loss of
proliferative potential in glycolytic cancer cells.
Discussion
The challenge of identifying protein–protein interaction inhib-
itors is signicant, with peptides and macromolecules
increasingly being viewed as the optimal scaﬀolds for this
purpose.4 We employed a genetically encoded high-throughput
screening platform to identify CP61, a cyclic peptide that binds
CtBP1 with 3 mM aﬃnity and disrupts CtBP heterodimerization
and homodimerization with 19 mM IC50 in vitro, and inhibits the
cellular function of CtBPs at 50 mM in cells. That the top 3 most
potent inhibitors identied were from the nonapeptide library
warrants further discussion. Our previous experience with cyclic
peptide protein–protein interaction inhibitors suggests that a
dipeptide or tripeptide motif is critical for inhibition, with the
rest of the cyclic peptide acting as a backbone that presents the
active motif to its target.48 As the active motif of CP61 would also
have been present in the random regions of the octapeptide and
heptapeptide libraries, one may either conclude that the whole
of CP61 is required for its activity, or ring size and the subse-
quent conformation of the active motif plays a signicant role
in the activity of cyclic peptide inhibitors. If correct, the latterChem. Sci.
Chemical Science Edge Article
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View Article Onlinesuggests that various sizes of macrocycles should be included in
libraries screened against protein–protein interactions. We are
currently conducting alanine scanning on CP61 to identify its
active motif.
CP61 is one of a handful of compounds that regulates
cellular function by inhibiting the protein–protein interaction
of a transcription factor,2–4 and was used as a chemical tool to
demonstrate that CtBP dimerization links cellular metabolism
with mitotic regulation. Classic mediators of cell cycle
progression such as APC/C and MYC, control the rate of
glycolysis through the regulation of transcriptional networks
and protein degradation pathways.11,49 High rates of glycolysis
are therefore matched to S phase of the cell cycle, when
demand for macromolecule synthesis is at its greatest;49 thus
the NAD+/NADH ratio is demonstrably reduced in S phase
cells.50 Given that glycolysis is an important requirement for
cell replication, and the well characterized role of cell cycle
checkpoints in restricting cell cycle progression in response to
a wide range of adverse signals (including metabolic stress), it
can be speculated that cells possess a mechanism that links a
deciency in glycolysis in S phase to the activation of subse-
quent cell cycle checkpoints. Loss of CtBPs results in activa-
tion of the spindle assemble checkpoint, though this
activation is ultimately futile and mitosis occurs with
improper DNA segregation.32,33 Combining this information
(from previous reports) with the data from this study, one can
conclude that CtBPs act in interphase to sense levels of
glycolytic ux and license key aspects of the subsequent
mitosis. In other words, normal DNA segregation is regulated
by a sensor of metabolic stress in the prior phases of the cell
cycle. Whilst the precise mechanism for this link between
CtBPs and mitotic delity remains to be fully explored, this is
an important new insight into the links between metabolism
and cell cycle control, and expands upon current precedents
linking normal energy and redox balance with the delity of
mitotic progression.9,11–15
In addition to providing insight into fundamental processes
of cell cycle control, CP61 further demonstrates the potential of
CtBPs as targets for the development of anti-cancer therapeutics
that target the epigenetic changes associated with cancer.31,36Methods
Construction of CtBP RTHS and SICLOPPS screening
All CtBP RTHS were constructed as previously described for the
ATIC RTHS.41 SICLOPPS libraries were constructed as described
in39 and screened as detailed in supplementary methods. The
activity of the SICLOPPS plasmids encoding the CtBP1/2
dimerisation inhibitors were ranked by drop spotting, and the
identity of the variable insert regions (encoding the cyclic
peptide) was revealed by DNA sequencing.Peptide synthesis
Linear peptides were synthesized using a Liberty One peptides
synthesizer (CEM Corp.) and were cyclized, TAT-tagged, and
characterized as detailed in supplementary methods.Chem. Sci.Proteins production
Plasmids for the expression of N-terminally GST-tagged CtBP1
and CtBP2 have been described previously.22 PET28a-based
vectors were generated for the expression of CtBP1 and CtBP2
with an N-terminal 6XHis-tag. CtBPs were expressed in E. coli
and puried using glutathione and nickel aﬃnity chromatog-
raphy respectively. Whilst bound to the aﬃnity matrix, CtBPs
were incubated for 30 min with 0.25 mM sodium pyruvate, to
promote the oxidation of bound NADH.17Size exclusion chromatography
Size exclusion chromatography was conducted using a Superdex
200 5/150 GL (GE Healthcare) pre-equilibrated with PBS. His–
CtBP1 (36 mL of a 1.3 mg mL1 solution in PBS) was incubated
with CP61 for 5 minutes prior to the addition of NADH and
loading onto the column.GST pull down assays and ELISA
GST pull down assays were conducted in 75 mL of pull-down
buﬀer (50 mM Tris–HCl pH 7.2, 150 mM NaCl, 5 mM EDTA pH
8.0, 1% IGEPAL CA-630, 10% glycerol, 5 mM DTT, protease
inhibitor mix) with 10 mgmL1 bacterial cell lysate for blocking
non-specic interactions. For ELISA, GST, GST–CtBP1 or GST–
CtBP2 was bound to glutathione-coated 96 well plates (Thermo
Scientic) (100 ng per well in 100 mL TBS-T [50 mM Tris–HCl,
150 mM NaCl, 0.05% Tween-20, pH 7.4]) for 1 h. Aer blocking
with 3% bovine serum albumin (BSA) (in 200 mL TBS), His–
CtBP1 or His–CtBP2 (600 ng per 1% BSA per 100 mL TBS) and
cyclic peptide were added and incubated for 30 min prior to
addition of NADH (to 0.5 mM) and incubated for 1 h. Detection
was with mouse anti-His Ab (Sigma) followed by sheep anti-
mouse-HRP (Sigma) (both in 1% BSA/TBS-T) and SuperSignal
chemiluminescent substrate (Thermo Scientic), using a Vari-
oskan Flash reader (Thermo Scientic).FRET assays
FRET assays were conducted in Greiner black 96-well half-area
plates, and were measured at room temperature using a Tecan
Innite M200 Pro micro-plate reader (excitation wavelength
285 nm, emission wavelength 425 nm). Assays were conducted
with 300 nM His–CtBP1 in a total volume of 50 mL. Gain setting
and z-position for the instrument were 178 and 18 278 mm for
assay in Fig. 4e, and 149 and 17 963 mm for the CP61 binding
assays (Fig. 4f).CtBP cellular compartmentalization assay
Expression vectors for CFP–CtBP1 and YFP–CtBP2 were con-
structed (based on pSCFP3A and pSYFP2 plasmids respectively),
and transfected into COS-7 cells. Expression and co-localization
of uorescent proteins was determined using an Olympus IX81
microscope with xcellence pro soware. Statistical comparisons
were performed using Fisher's exact analysis of contingency
tables (GraphPad Prism).This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineAberrant mitosis assays
siRNA transfection, micronuclei counting, time lapse video
microscopy and microinjections were performed as previously
described,32,33 except that times lapse images were captured
every 30 min. Data from micronuclei assays is presented as
mean  SEM from triplicate wells from a representative of at
least two independent experiments, statistical analysis was by
ANOVA one way parametric test and Tukey's post hoc test. For
microinjection, cells were synchronized in medium containing
0.1% fetal calf serum for 48 h, prior to release by increasing the
serum concentration to 10%. Cells were microinjected 20 h post
release with FITC-dextran (70 kDa, 1 mg mL1) plus cyclic peptide
or GST–CtBP fusion protein in PBS. Peptides were injected at 50
mM; GST, GST–CtBPDD and GST–CtBPDDM proteins at 1 mg mL1
in PBS. Cell penetrating peptides were added to the medium of
asynchronous cell cultures. All cell-based experiments were
repeated at least twice; data from a representative experiment
being shown. Statistical comparisons of cell count data were
performed using Fisher's exact analysis of contingency tables
(GraphPad Prism).Colony forming assays
Cells were plated at 2500 cells per well in 96 wells plates and
incubated with 50 mM TAT, CP61–TAT, or DMSO alone for 48 h
prior to re-plating of 10% of the cells into a well of a 6 well plate.
10 days later cells were xed, stained with Giemsa (Sigma
Aldrich), and colonies counted. Data is presented as mean 
SEM from triplicate wells from a representative of three inde-
pendent experiments, statistical analysis was by two tailed,
paired Students t-test.Acknowledgements
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